What ARM’s expected debut means for the IPO market and SoftBank
Billionaire Masayoshi Son, chairman and chief executive officer of SoftBank Group Corp., speaks in front of a screen displaying the ARM Holdings logo during a news conference in Tokyo on July 28, 2016.
Tomohiro Ohsumi | Bloomberg | Getty Images
Arm, which is owned by SoftBank, filed for its initial public offering Monday. The firm’s stock market debut will be a major test for the IPO market, which has more or less closed off from new listings due to rising interest rates which have hammered appetite for risky assets in the last year or so.
Arm is one of the most important companies in technology. Its chip designs found in nearly all the world’s smartphones, including Apple iPhones and most Android devices. Its debut will be a big deal for an IPO market that’s been in the doldrums since 2022, but the company’s listing has big implications for SoftBank as well.
SoftBank has been attempting to bounce back from a grim tech market by reining in on its growth-focused investments and pivoting its focus to artificial intelligence, the hot topic of the hour in tech.
What is Arm?
Arm, which is headquartered in Cambridge, England, designed the architecture of chips found in 99% of all smartphones.
The company traces its history to an early computing company known as Acorn Computers. In 1990, Acorn spun out a new company named Advanced RISC Machines, structured as a joint venture between Acorn, Apple and U.S. chipmaker VLSI Technology.
Arm isn’t a chipmaker itself. Rather, the company is responsible for coming up with the “architectures” — or overall designs, including components and programming language instructions that other companies use to build chips. Its original value was designing chips with extremely low energy consumption compared with the X86 chips common in personal computers at the time. It’s seen as something of a neutral party or “Switzerland” in tech, since its designs are used in nearly smartphone processors, including those made by Apple, and increasingly, server and laptop processors as well.
It’s also often considered the crown jewel of the U.K.’s technology sector.
Speaking with CNBC at a developer conference in October 2022, Arm CEO Rene Haas said that companies can’t afford not to work with the company, given its technology is embedded in virtually every device out there.
“Given the fact that we license the technology to all the major players in the industry, no one can really afford to miss a product cycle or scale back on R&D or not do a product,” Haas said at the time.
Arm’s business model is to license the intellectual property for these architectures so that they can build systems around them. In recent years, ARM has tried to sell its own designs for processors, a more lucrative business than just licensing the underlying architecture technology.
SoftBank agreed to acquire Arm in 2016 for $32 billion, which at the time was the biggest-ever purchase of a European technology company. SoftBank at the time said it was acquiring the business to gain a foothold in the growing internet of things sector. IoT, is a small part of the firm’s business, but at the time it was a much-hyped part of tech.
Not just for wearables or smart home appliances, Arm has been expanding its semiconductors to other uses such as connected cars.
For the quarter ended June 30, the company generated 88.5 billion Japanese yen ($605.5 million), according to an earnings release from SoftBank.
But the company is also facing headwinds from a slowdown in demand for products like smartphones, which has hit chip firms across the board. Arm’s net sales fell 4.6% year-on-year in the second quarter.
The unit also swung to a 9.5 billion yen loss, having made a profit of 29.8 billion yen in the same period a year earlier.
Beleaguered sale to Nvidia
SoftBank originally tried to sell Arm to chip giant Nvidia, but the deal faced pushback from regulators, who raised concerns over competition and national security. Nvidia is a behemoth in the world of semiconductors, and the company is now benefiting heavily from the boom in AI applications as demand for its GPUs soars.
Since then, SoftBank has opted to list Arm as an independent company. The Japanese tech investing giant is reportedly looking to purchase the remaining 25% stake in Arm that it does not currently own from its massive $100 billion Vision Fund.
In the U.K., which has sought to boost its domestic chip industry through up to £1 billion ($1.3 billion) in investments, Arm is seen as strategically important.
The change of the company’s ownership to foreign hands is seen as a thorny topic for the domestic tech industry, not least due to concerns that it undermines the U.K.’s “tech sovereignty,” an issue that has cropped up throughout Europe as officials look to reduce dependence on technology from the U.S. and other nations.
The government had pushed aggressively for Arm to list in London, however the company opted to go with New York for its debut instead, dealing a blow to the London stock exchange.
Testing a choppy IPO market
SoftBank is pushing ahead with a listing of Arm even as U.S. markets have been in an unsteady state. Technology valuations have fallen sharply from the peak of the 2021 tech boom.
That year, shares of newly minted public companies such as Palantir and UiPath rose to seismic levels as investors grew excited by their growth prospects in the boom times.
Arm filed confidentially for a listing in the U.S. earlier this year. It’s not yet clear what valuation SoftBank is seeking for Arm, however reports have pegged the prospective market value at between $60 billion and $70 billion.
As well as being a bellwether for the chip industry, Arm plays a role in the AI space — and is increasingly touting itself as an AI company. Investors will be watching out for the company’s S-1 filing to see how it sees the technology benefiting its business over time.
In May, Arm unveiled two new chipsets targeted at machine learning applications. One, a new CPU called Cortex-4, is a chipset that delivers faster machine-learning performance and consumes 40% less power than its predecessor, according to Arm. The other, a GPU called G720, offers better performance and uses up 22% less memory bandwidth than its predecessor, Arm said.
“Arm remains committed to developing and testing our GPUs against new applications for machine learning (ML),” the company said in a May 29 blog post announcing the products.
High-powered chips such as those offered by Nvidia and AMD are crucial to AI applications, which require lots of computing power to run smoothly. Earlier this month, Nvidia unveiled its new Grace Hopper chip for generative AI applications, which is based on Arm architecture.
SoftBank is banking on the growth in AI to lift the prospects of its Vision Fund, which has flagged in tandem with souring bets on firms like WeWork, China’s ride-hailing giant Didi Global, and Uber, the latter of which the Vision Fund has since shed its holdings.
SoftBank’s CFO Yoshimitsu Goto said during the company’s June quarter earnings call that the company has been “carefully and slowly emerging back to investment activity,” with a focus on AI investments.
SoftBank said its Vision Fund booked an investment gain of 159.8 billion yen, its first gain in five consecutive quarters. SoftBank said the fund mainly benefited from investments in its own subsidiaries — including Arm.
That still came after SoftBank’s Vision Fund reported a record 4.3 trillion yen loss in the fiscal year ending Mar. 31.
The Japanese tech giant has been starting to talk up its investments in AI recently. In July, the company led a $65 million investment in U.K. insurance technology company Tractable.
– CNBC’s Kif Leswing contributed to this story.
The Hims app arranged on a smartphone in New York on Feb. 12, 2025.
Gabby Jones | Bloomberg | Getty Images
Hims & Hers Health shares closed up 5% on Tuesday after the company announced patients can access Eli Lilly‘s weight loss medication Zepbound and diabetes drug Mounjaro, as well as the generic injection liraglutide, through its platform.
Zepbound, Mounjaro and liraglutide are part of the class of weight loss medications called GLP-1s, which have exploded in popularity in recent years. Hims & Hers launched a weight loss program in late 2023, but its GLP-1 offerings have evolved as the company has contended with a volatile supply and regulatory environment.
Lilly’s weekly injections Zepbound and Mounjaro will cost patients $1,899 a month, according to the Hims & Hers website. The generic liraglutide will cost $299 a month, but it requires a daily injection and can be less effective than other GLP-1 medications.
“As we look ahead, we plan to continue to expand our weight loss offering to deliver an even more holistic, personalized experience,” Dr. Craig Primack, senior vice president of weight loss at Hims & Hers, wrote in a blog post.
A Lilly spokesperson said in a statement that the company has “no affiliation” with Hims & Hers and noted that Zepbound is available at lower costs for people who are insured for the product or for those who buy directly from the company.
In May, Hims & Hers started prescribing compounded semaglutide, the active ingredient in Novo Nordisk‘s GLP-1 weight loss medications Ozempic and Wegovy. The offering was immensely popular and helped generate more than $225 million in revenue for the company in 2024.
But compounded drugs can traditionally only be mass produced when the branded medications treatments are in shortage. The U.S. Food and Drug Administration announced in February that the shortage of semaglutide injections products had been resolved.
That meant Hims & Hers had to largely stop offering the compounded medications, though some consumers may still be able to access personalized doses if it’s clinically applicable.
During the company’s quarterly call with investors in February, Hims & Hers said its weight loss offerings will primarily consist of its oral medications and liraglutide. The company said it expects its weight loss offerings to generate at least $725 million in annual revenue, excluding contributions from compounded semaglutide.
But the company is still lobbying for compounded medications. A pop up on Hims & Hers’ website, which was viewed by CNBC, encourages users to “use your voice” and urge Congress and the FDA to preserve access to compounded treatments.
With Tuesday’s rally, Hims and Hers shares are up about 27% in 2025 after soaring 172% last year.
WATCH: Hims & Hers shares tumble over concerns around weight-loss business
Meta CEO Mark Zuckerberg holds a smartphone as he makes a keynote speech at the Meta Connect annual event at the company’s headquarters in Menlo Park, California, on Sept. 25, 2024.
Manuel Orbegozo | Reuters
Meta’s head of artificial intelligence research announced Tuesday that she will be leaving the company.
Joelle Pineau, the company’s vice president of AI research, announced her departure in a LinkedIn post, saying her last day at the social media company will be May 30.
Her departure comes at a challenging time for Meta. CEO Mark Zuckerberg has made AI a top priority, investing billions of dollars in an effort to become the market leader ahead of rivals like OpenAI and Google.
Zuckerberg has said that it is his goal for Meta to build an AI assistant with more than 1 billion users and artificial general intelligence, which is a term used to describe computers that can think and take actions comparable to humans.
“As the world undergoes significant change, as the race for AI accelerates, and as Meta prepares for its next chapter, it is time to create space for others to pursue the work,” Pineau wrote. “I will be cheering from the sidelines, knowing that you have all the ingredients needed to build the best AI systems in the world, and to responsibly bring them into the lives of billions of people.”
Vice President of AI Research and Head of FAIR at Meta Joelle Pineau attends a technology demonstration at the META research laboratory in Paris on February 7, 2025.
Stephane De Sakutin | AFP | Getty Images
Pineau was one of Meta’s top AI researchers and led the company’s fundamental AI research unit, or FAIR, since 2023. There, she oversaw the company’s cutting-edge computer science-related studies, some of which are eventually incorporated into the company’s core apps.
She joined the company in 2017 to lead Meta’s Montreal AI research lab. Pineau is also a computer science professor at McGill University, where she is a co-director of its reasoning and learning lab.
Some of the projects Pineau helped oversee include Meta’s open-source Llama family of AI models and other technologies like the PyTorch software for AI developers.
Pineau’s departure announcement comes a few weeks ahead of Meta’s LlamaCon AI conference on April 29. There, the company is expected to detail its latest version of Llama. Meta Chief Product Officer Chris Cox, to whom Pineau reported to, said in March that Llama 4 will help power AI agents, the latest craze in generative AI. The company is also expected to announce a standalone app for its Meta AI chatbot, CNBC reported in February.
“We thank Joelle for her leadership of FAIR,” a Meta spokesperson said in a statement. “She’s been an important voice for Open Source and helped push breakthroughs to advance our products and the science behind them.”
Pineau did not reveal her next role but said she “will be taking some time to observe and to reflect, before jumping into a new adventure.”
-
Sports2 years ago‘Storybook stuff’: Inside the night Bryce Harper sent the Phillies to the World Series
-
Sports12 months agoStory injured on diving stop, exits Red Sox game
-
Sports1 year agoGame 1 of WS least-watched in recorded history
-
Sports2 years agoMLB Rank 2023: Ranking baseball’s top 100 players
-
Sports4 years ago
Team Europe easily wins 4th straight Laver Cup
-
Environment2 years agoJapan and South Korea have a lot at stake in a free and open South China Sea
-
Environment2 years agoGame-changing Lectric XPedition launched as affordable electric cargo bike
-
Business3 years agoBank of England’s extraordinary response to government policy is almost unthinkable | Ed Conway